European Commission approves osimertinib for adjuvant treatment of early-stage EGFR mutated non-small cell lung cancer

The approval is based on data from the Phase III ADAURA trial, which found treatment with osimertinib following surgery reduced risk of disease recurrence or death by 83% in patients with stage II and IIIA disease, and by 80% in the overall population (stage IB-IIIA disease).

Source:

PharmaTimes